Effect of a Low Glycemic Index on Metabolic Syndrome
- Conditions
- Metabolic Syndrome X
- Interventions
- Behavioral: Mediterranean DietBehavioral: Low Glycemic Index Mediterranean DietBehavioral: Low Glycemic Index Diet
- Registration Number
- NCT02356952
- Lead Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
- Brief Summary
Metabolic Syndrome (MetS) is a cluster of multiple risk factors of metabolic origin associated with an increased risk of cardiovascular disease, type 2 diabetes mellitus and other diseases, including some cancers. There has been an increased interest of researchers in the relationship between MetS and diet and, specifically, Mediterranean diet would be beneficial for people with high risk of developing MetS or individuals with established MetS.
- Detailed Description
Metabolic Syndrome (MetS) is a cluster of multiple risk factors of metabolic origin, associated with an increased risk of cardiovascular disease, type 2 diabetes mellitus and other diseases, including some cancers. The National Cholesterol Education Program's Adult Treatment Panel III (NCEP-ATP III) defines MetS the presence of at least three of five diagnostic criteria consisting in the measure of waist circumference, fasting glucose, systolic pressure and/or diastolic blood pressure, serum triglycerides and HDL cholesterol. The level of physical activity, smoking habits, low social class membership as well as low level of education and even a mild degree of chronic inflammation have been associated with an increased risk of MetS. Recently, there has been an increased interest of researchers in the relationship between MetS and diet, and more specifically Mediterranean Diet (MD). A problem of the contemporary MD is the quality of carbohydrates as the foods rich in carbohydrates consumed actually, such as white bread and some type of pasta, are produced with refined flour, at high glycemic index (GI) and load (GL). There are numerous studies showing that taking large amounts of high GI and GL foods is a risk factor for coronary heart disease and type 2 diabetes. To our knowledge there is no diet trial that compared the health effects of Mediterranean diets with different quality of carbohydrates. Objective of this study was to compare, in a randomized clinical trial, the effects of a simple MD, a Low Glycemic Index diet (LGID), and a Low Glycemic Index MD (LGIMD) on MetS, MetS components and other metabolic variables. For this reason, after a baseline examination, participants were randomly divided into three groups, each receiving a specific dietary intervention, and all the parameters measured at the first visit were examined again at months third and sixth.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 163
- MetS, Subject enrolled in the MICOL study in 2005-2006
- Insulin treatment, Not enrolled in the MICOL study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Mediterranean Diet Mediterranean Diet Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods). Low Glycemic Index Mediterranean Diet Low Glycemic Index Mediterranean Diet Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods). Low Glycemic Index Diet Low Glycemic Index Diet Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
- Primary Outcome Measures
Name Time Method Change from Baseline in MetS score at six months 6 months
- Secondary Outcome Measures
Name Time Method Change from Baseline in Serum Triglycerides at six months 6 months Height Baseline Change from Baseline in Systolic blood pressure at six months 6 months Change from Baseline in Serum Cholesterol at six months 6 months Change from Baseline in Serum ALT at six months 6 months Change from Baseline in Serum Fasting Glucose at six months 6 months Change from Baseline in Serum insulin at six months 6 months Change from Baseline in Serum glycated hemoglobin at six months 6 months Change from Baseline in Serum HDL Cholesterol at six months 6 months Change from Baseline in Body Weight at six months 6 months Change from Baseline in Diastolic blood pressure at six months 6 months Change from Baseline in Bioimpedenziometry at six months 6 months
Trial Locations
- Locations (1)
Laboratory of Epidemiology and Biostatistics-IRCCS Saverio de Bellis
🇮🇹Castellana Grotte, BA, Italy